Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors

OBJECTIVE: To determine whether changes in standard and novel risk factors during the ACT NOW trial explained the slower rate of CIMT progression with pioglitazone treatment in persons with prediabetes. METHODS AND RESULTS: CIMT was measured in 382 participants at the beginning and up to three addit...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Saremi, Aramesh, Schwenke, Dawn C., Buchanan, Thomas A., Hodis, Howard N., Mack, Wendy J., Banerji, MaryAnn, Bray, George A., Clement, Stephen C., Henry, Robert R., Kitabchi, Abbas E., Mudaliar, Sunder, Ratner, Robert E., Stentz, Frankie B., Musi, Nicolas, Tripathy, Devjit, DeFronzo, Ralph A., Reaven, Peter D.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2012
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3908828/
https://ncbi.nlm.nih.gov/pubmed/23175674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.112.300346
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια